Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec;24(12):371-382.
doi: 10.1007/s11926-022-01089-z. Epub 2022 Oct 12.

Neurosarcoidosis: Phenotypes, Approach to Diagnosis and Treatment

Affiliations
Review

Neurosarcoidosis: Phenotypes, Approach to Diagnosis and Treatment

Jeanne Gosselin et al. Curr Rheumatol Rep. 2022 Dec.

Abstract

Purpose of review: The aim of this review is to provide an update of clinical presentation, diagnosis, differential diagnoses, and treatment according to recent evidence.

Recent findings: Neurosarcoidosis remains a diagnosis of exclusion, with infectious and malignant etiologies recognized as important mimickers. Corticosteroids remain as first-line therapy. In recent years, however, studies have demonstrated the effectiveness of anti-tumor necrosis factor (anti-TNF) therapy in the treatment of neurosarcoidosis, leading to improved outcomes. Neurosarcoidosis is a granulomatous disease with protean manifestations that may affect any part of the central and peripheral nervous system. It has many mimickers, and potentially devastating complications necessitating long-term follow-up. Early initiation of treatment, particularly with anti-TNF therapy, may lead to better outcomes and fewer relapses. There is an unmet need for randomized controlled trials that provide robust data to guide therapy and the long-term management of neurosarcoidosis patients.

Keywords: CNS; Neurosarcoidosis; Sarcoidosis; Treatment.

PubMed Disclaimer

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Yoon HY, Kim HM, Kim YJ, Song JW. Prevalence and incidence of sarcoidosis in Korea: a nationwide population-based study. Respir Res. 2018;19(1):158. https://doi.org/10.1186/s12931-018-0871-3 . - DOI - PubMed - PMC
    1. Pietinalho A, Hiraga Y, Hosoda Y, Löfroos AB, Yamaguchi M, Selroos O. The frequency of sarcoidosis in Finland and Hokkaido, Japan. A comparative epidemiological study. Sarcoidosis. 1995;12(1):61–7. - PubMed
    1. Baughman RP, Field S, Costabel U, Crystal RG, Culver DA, Drent M, et al. Sarcoidosis in America. Analysis Based on Health Care Use. Ann Am Thorac Soc. 2016;13(8):1244–52. https://doi.org/10.1513/AnnalsATS.201511-760OC . - DOI - PubMed
    1. Ungprasert P, Matteson EL. Neurosarcoidosis. Rheum Dis Clin North Am. 2017;43(4):593–606. https://doi.org/10.1016/j.rdc.2017.06.008 . - DOI - PubMed
    1. Dumas O, Abramovitz L, Wiley AS, Cozier YC, Camargo CA Jr. Epidemiology of sarcoidosis in a prospective cohort study of U.S. women. Ann Am Thorac Soc. 2016;13(1):67–71. https://doi.org/10.1513/AnnalsATS.201508-568BC . - DOI - PubMed - PMC

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources